Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
Clinical trial NCT03700320 · COMPLETED
Trial details
- NCT number
- NCT03700320
- Sponsor
- Allergan
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-08
- Primary completion
- 2020-05-21
- Enrollment
- 744
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.